首页> 外文期刊>Saudi Pharmaceutical Journal >Erythrocyte nanovesicles
【24h】

Erythrocyte nanovesicles

机译:红细胞纳米囊泡

获取原文
获取外文期刊封面目录资料

摘要

Nanovesicles (NVs) represent a novel transporter for cell signals to modify functions of target cells. Therefore, NVs play many roles in both physiological and pathological processes. This report highlights biogenesis, composition and biological roles of erythrocytes derived nanovesicles (EDNVs). Furthermore, we address utilization of EDNVs as novel drug delivery cargo as well as therapeutic target. EDNVs are lipid bilayer vesicles rich in phospholipids, proteins, lipid raft, and hemoglobin. In vivo EDNVs biogenesis is triggered by an increase of intracellular calcium levels, ATP depletion and under effect of oxidative stress conditions. However, in vitro production of EDNVs can be achieved via hypotonic treatment and extrusion of erythrocyte. NVs can be used as biomarkers for diagnosis, monitoring of therapy and drug delivery system. Many therapeutic agents are suggested to decrease NVs biogenesis.
机译:纳米囊泡(NVs)代表一种新型的转运蛋白,用于细胞信号修饰靶细胞的功能。因此,NVS在生理和病理过程中都起着许多作用。该报告重点介绍了红细胞衍生的纳米囊泡(EDNV)的生物发生,组成和生物学作用。此外,我们致力于将EDNV用作新型药物和治疗靶标。 EDNV是富含磷脂,蛋白质,脂质筏和血红蛋白的脂质双层囊泡。体内EDNV的生物发生是由细胞内钙水平增加,ATP耗竭以及在氧化应激条件下触发的。但是,可以通过低渗处理和红细胞挤出来实现EDNV的体外生产。 NV可以用作诊断,监测治疗和药物输送系统的生物标志物。建议使用许多治疗剂来减少NVs生物发生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号